Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.36 |
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | GPR6 | P46095 | 6/20 | 0.35 |
| ▸ | MASP2 | O00187 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374792 | 0.84 | F2 (0.35) | F2MASP2HRH3 | |
| Trifluoroacetic Acid SCHEMBL1371687 | 0.82 | F2 (0.38) | F2GPR6MASP2CHIT1 | |
| SCHEMBL6277439 | 0.79 | ARG1 (0.41) | GRIK1ARG1HRH3 | |
| SCHEMBL1814892 | 0.79 | ARG1 (0.41) | GRIK1ARG1HRH3 | |
| SCHEMBL29351610 | 0.76 | GRIK1 (0.51) | F2GRIK1ARG1MASP2HRH3 | |
| SCHEMBL2170540 | 0.74 | F2 (0.41) | F2 | |
| SCHEMBL1372386 | 0.74 | F2 (0.41) | F2 | |
| SCHEMBL11234759 | 0.73 | HRH3 (0.55) | F2GRIK1ARG1MASP2HRH3 | |
| SCHEMBL31080928 | 0.73 | HRH3 (0.55) | F2GRIK1ARG1MASP2HRH3 | |
| SCHEMBL31524208 | 0.73 | HRH3 (0.55) | F2GRIK1ARG1MASP2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | F2 4544/4885GRIK1 471/4885ARG1 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.